nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—hematologic cancer	0.401	1	CbGaD
Rasagiline—CYP1A2—Anagrelide—hematologic cancer	0.051	0.217	CbGbCtD
Rasagiline—CYP1A2—Carmustine—hematologic cancer	0.0268	0.114	CbGbCtD
Rasagiline—CYP1A2—Methoxsalen—hematologic cancer	0.0228	0.097	CbGbCtD
Rasagiline—CYP1A2—Bortezomib—hematologic cancer	0.0217	0.0922	CbGbCtD
Rasagiline—CYP1A2—Daunorubicin—hematologic cancer	0.0207	0.0882	CbGbCtD
Rasagiline—CYP1A2—Alitretinoin—hematologic cancer	0.0203	0.0864	CbGbCtD
Rasagiline—CYP1A2—Thalidomide—hematologic cancer	0.0189	0.0803	CbGbCtD
Rasagiline—CYP1A2—Dacarbazine—hematologic cancer	0.0162	0.0691	CbGbCtD
Rasagiline—CYP1A2—Imatinib—hematologic cancer	0.0159	0.0676	CbGbCtD
Rasagiline—CYP1A2—Dasatinib—hematologic cancer	0.0127	0.0543	CbGbCtD
Rasagiline—CYP1A2—Etoposide—hematologic cancer	0.00794	0.0338	CbGbCtD
Rasagiline—BCL2—hematopoietic system—hematologic cancer	0.00327	0.152	CbGeAlD
Rasagiline—BCL2—gonad—hematologic cancer	0.00249	0.115	CbGeAlD
Rasagiline—BCL2—blood—hematologic cancer	0.00217	0.101	CbGeAlD
Rasagiline—BCL2—bone marrow—hematologic cancer	0.0021	0.0974	CbGeAlD
Rasagiline—BCL2—lung—hematologic cancer	0.0019	0.0882	CbGeAlD
Rasagiline—BCL2—testis—hematologic cancer	0.00179	0.0832	CbGeAlD
Rasagiline—BCL2—Tretinoin—Alitretinoin—hematologic cancer	0.00137	0.5	CbGdCrCtD
Rasagiline—BCL2—Isotretinoin—Alitretinoin—hematologic cancer	0.00137	0.5	CbGdCrCtD
Rasagiline—MAOB—hematopoietic system—hematologic cancer	0.00136	0.0632	CbGeAlD
Rasagiline—BCL2—lymph node—hematologic cancer	0.0013	0.0603	CbGeAlD
Rasagiline—CYP1A2—hematopoietic system—hematologic cancer	0.000971	0.045	CbGeAlD
Rasagiline—MAOB—blood—hematologic cancer	0.000903	0.0419	CbGeAlD
Rasagiline—MAOB—lung—hematologic cancer	0.000792	0.0367	CbGeAlD
Rasagiline—MAOB—testis—hematologic cancer	0.000747	0.0347	CbGeAlD
Rasagiline—CYP1A2—blood—hematologic cancer	0.000643	0.0298	CbGeAlD
Rasagiline—CYP1A2—lung—hematologic cancer	0.000564	0.0261	CbGeAlD
Rasagiline—MAOB—lymph node—hematologic cancer	0.000542	0.0251	CbGeAlD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	1.78e-05	0.00014	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—hematologic cancer	1.78e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—hematologic cancer	1.78e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TSC2—hematologic cancer	1.77e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CRP—hematologic cancer	1.77e-05	0.00014	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.77e-05	0.00014	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALOX5—hematologic cancer	1.76e-05	0.000139	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HSPA5—hematologic cancer	1.76e-05	0.000139	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—hematologic cancer	1.75e-05	0.000138	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	1.73e-05	0.000137	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—hematologic cancer	1.73e-05	0.000137	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTPRC—hematologic cancer	1.72e-05	0.000136	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.71e-05	0.000135	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—hematologic cancer	1.71e-05	0.000135	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CALR—hematologic cancer	1.71e-05	0.000135	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NUP98—hematologic cancer	1.71e-05	0.000135	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGFR3—hematologic cancer	1.71e-05	0.000134	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK14—hematologic cancer	1.69e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—hematologic cancer	1.69e-05	0.000133	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—hematologic cancer	1.67e-05	0.000131	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ADCY7—hematologic cancer	1.66e-05	0.000131	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOA3—hematologic cancer	1.66e-05	0.000131	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FBXW7—hematologic cancer	1.65e-05	0.00013	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NUP214—hematologic cancer	1.65e-05	0.00013	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—HRAS—hematologic cancer	1.65e-05	0.00013	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NFKBIA—hematologic cancer	1.62e-05	0.000127	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—BAD—hematologic cancer	1.62e-05	0.000127	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCG2—hematologic cancer	1.61e-05	0.000127	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—MTR—hematologic cancer	1.61e-05	0.000127	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITGA4—hematologic cancer	1.6e-05	0.000126	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD40—hematologic cancer	1.6e-05	0.000126	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD44—hematologic cancer	1.6e-05	0.000126	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	1.6e-05	0.000126	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ENO2—hematologic cancer	1.58e-05	0.000125	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CBL—hematologic cancer	1.58e-05	0.000124	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD80—hematologic cancer	1.57e-05	0.000124	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KIT—hematologic cancer	1.57e-05	0.000123	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL3—hematologic cancer	1.56e-05	0.000123	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—hematologic cancer	1.55e-05	0.000122	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA1—hematologic cancer	1.55e-05	0.000122	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	1.55e-05	0.000122	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTPN11—hematologic cancer	1.54e-05	0.000121	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTPN1—hematologic cancer	1.54e-05	0.000121	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTT1—hematologic cancer	1.54e-05	0.000121	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RASGRP1—hematologic cancer	1.51e-05	0.000119	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD79A—hematologic cancer	1.51e-05	0.000119	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SYK—hematologic cancer	1.51e-05	0.000119	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HSP90AA1—hematologic cancer	1.51e-05	0.000119	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SDC1—hematologic cancer	1.5e-05	0.000118	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FOS—hematologic cancer	1.49e-05	0.000118	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CREB1—hematologic cancer	1.49e-05	0.000117	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CASP8—hematologic cancer	1.46e-05	0.000115	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6R—hematologic cancer	1.45e-05	0.000115	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—AKT1—hematologic cancer	1.45e-05	0.000115	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT1—hematologic cancer	1.45e-05	0.000115	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CREBBP—hematologic cancer	1.45e-05	0.000114	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.45e-05	0.000114	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	1.45e-05	0.000114	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hematologic cancer	1.45e-05	0.000114	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—hematologic cancer	1.44e-05	0.000114	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—hematologic cancer	1.44e-05	0.000113	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—hematologic cancer	1.43e-05	0.000113	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—hematologic cancer	1.42e-05	0.000112	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DQA1—hematologic cancer	1.39e-05	0.00011	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAP2K1—hematologic cancer	1.39e-05	0.000109	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CD—hematologic cancer	1.38e-05	0.000108	CbGpPWpGaD
Rasagiline—BCL2—Immune System—GRB2—hematologic cancer	1.36e-05	0.000107	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDGFA—hematologic cancer	1.36e-05	0.000107	CbGpPWpGaD
Rasagiline—Decreased appetite—Betamethasone—hematologic cancer	1.34e-05	6.3e-05	CcSEcCtD
Rasagiline—Nausea—Irinotecan—hematologic cancer	1.34e-05	6.29e-05	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—hematologic cancer	1.34e-05	6.29e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—KITLG—hematologic cancer	1.34e-05	0.000105	CbGpPWpGaD
Rasagiline—Immune system disorder—Epirubicin—hematologic cancer	1.33e-05	6.28e-05	CcSEcCtD
Rasagiline—Infection—Prednisone—hematologic cancer	1.33e-05	6.28e-05	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—hematologic cancer	1.33e-05	6.27e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.33e-05	6.26e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.33e-05	6.26e-05	CcSEcCtD
Rasagiline—Back pain—Methotrexate—hematologic cancer	1.33e-05	6.26e-05	CcSEcCtD
Rasagiline—Chills—Epirubicin—hematologic cancer	1.33e-05	6.24e-05	CcSEcCtD
Rasagiline—Pruritus—Etoposide—hematologic cancer	1.32e-05	6.24e-05	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—hematologic cancer	1.32e-05	0.000104	CbGpPWpGaD
Rasagiline—Shock—Prednisone—hematologic cancer	1.32e-05	6.21e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—FGF2—hematologic cancer	1.32e-05	0.000104	CbGpPWpGaD
Rasagiline—Nervous system disorder—Prednisone—hematologic cancer	1.32e-05	6.19e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—ABL1—hematologic cancer	1.31e-05	0.000103	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT5A—hematologic cancer	1.31e-05	0.000103	CbGpPWpGaD
Rasagiline—Alopecia—Epirubicin—hematologic cancer	1.31e-05	6.14e-05	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—hematologic cancer	1.31e-05	0.000103	CbGpPWpGaD
Rasagiline—Skin disorder—Prednisone—hematologic cancer	1.3e-05	6.14e-05	CcSEcCtD
Rasagiline—Nausea—Gemcitabine—hematologic cancer	1.3e-05	6.13e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	1.3e-05	0.000103	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3R1—hematologic cancer	1.3e-05	0.000102	CbGpPWpGaD
Rasagiline—Vomiting—Cisplatin—hematologic cancer	1.3e-05	6.12e-05	CcSEcCtD
Rasagiline—Hyperhidrosis—Prednisone—hematologic cancer	1.3e-05	6.11e-05	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—hematologic cancer	1.29e-05	6.09e-05	CcSEcCtD
Rasagiline—Rash—Cisplatin—hematologic cancer	1.29e-05	6.07e-05	CcSEcCtD
Rasagiline—Dermatitis—Cisplatin—hematologic cancer	1.29e-05	6.06e-05	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—hematologic cancer	1.29e-05	6.05e-05	CcSEcCtD
Rasagiline—Diarrhoea—Etoposide—hematologic cancer	1.28e-05	6.03e-05	CcSEcCtD
Rasagiline—Anorexia—Prednisone—hematologic cancer	1.28e-05	6.02e-05	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—hematologic cancer	1.28e-05	6.01e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CD44—hematologic cancer	1.28e-05	0.000101	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NQO1—hematologic cancer	1.28e-05	0.000101	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Methotrexate—hematologic cancer	1.28e-05	6e-05	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—hematologic cancer	1.27e-05	5.98e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Dexamethasone—hematologic cancer	1.27e-05	5.98e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Betamethasone—hematologic cancer	1.27e-05	5.98e-05	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—hematologic cancer	1.27e-05	5.97e-05	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—hematologic cancer	1.27e-05	5.96e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JAK2—hematologic cancer	1.26e-05	9.96e-05	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.26e-05	5.93e-05	CcSEcCtD
Rasagiline—Gastrointestinal pain—Betamethasone—hematologic cancer	1.26e-05	5.93e-05	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—hematologic cancer	1.26e-05	5.93e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CD86—hematologic cancer	1.25e-05	9.87e-05	CbGpPWpGaD
Rasagiline—Hypersensitivity—Triamcinolone—hematologic cancer	1.25e-05	5.89e-05	CcSEcCtD
Rasagiline—Back pain—Epirubicin—hematologic cancer	1.24e-05	5.85e-05	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—hematologic cancer	1.24e-05	5.84e-05	CcSEcCtD
Rasagiline—Malaise—Methotrexate—hematologic cancer	1.24e-05	5.83e-05	CcSEcCtD
Rasagiline—Dizziness—Etoposide—hematologic cancer	1.24e-05	5.83e-05	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—hematologic cancer	1.24e-05	5.82e-05	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—hematologic cancer	1.23e-05	5.81e-05	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—hematologic cancer	1.23e-05	5.81e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MDM2—hematologic cancer	1.23e-05	9.72e-05	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Doxorubicin—hematologic cancer	1.23e-05	5.8e-05	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—hematologic cancer	1.23e-05	5.79e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CD40LG—hematologic cancer	1.23e-05	9.68e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HGF—hematologic cancer	1.23e-05	9.68e-05	CbGpPWpGaD
Rasagiline—Chills—Doxorubicin—hematologic cancer	1.23e-05	5.77e-05	CcSEcCtD
Rasagiline—Urticaria—Betamethasone—hematologic cancer	1.22e-05	5.76e-05	CcSEcCtD
Rasagiline—Urticaria—Dexamethasone—hematologic cancer	1.22e-05	5.76e-05	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.22e-05	5.75e-05	CcSEcCtD
Rasagiline—Dizziness—Prednisolone—hematologic cancer	1.22e-05	5.75e-05	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—hematologic cancer	1.22e-05	9.61e-05	CbGpPWpGaD
Rasagiline—Asthenia—Triamcinolone—hematologic cancer	1.22e-05	5.74e-05	CcSEcCtD
Rasagiline—Body temperature increased—Dexamethasone—hematologic cancer	1.22e-05	5.73e-05	CcSEcCtD
Rasagiline—Abdominal pain—Dexamethasone—hematologic cancer	1.22e-05	5.73e-05	CcSEcCtD
Rasagiline—Body temperature increased—Betamethasone—hematologic cancer	1.22e-05	5.73e-05	CcSEcCtD
Rasagiline—Abdominal pain—Betamethasone—hematologic cancer	1.22e-05	5.73e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FGF1—hematologic cancer	1.21e-05	9.57e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—hematologic cancer	1.21e-05	9.57e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CSF2—hematologic cancer	1.21e-05	9.57e-05	CbGpPWpGaD
Rasagiline—Nausea—Cisplatin—hematologic cancer	1.21e-05	5.71e-05	CcSEcCtD
Rasagiline—Insomnia—Prednisone—hematologic cancer	1.21e-05	5.71e-05	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—hematologic cancer	1.21e-05	5.69e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—CYCS—hematologic cancer	1.21e-05	9.51e-05	CbGpPWpGaD
Rasagiline—Paraesthesia—Prednisone—hematologic cancer	1.21e-05	5.67e-05	CcSEcCtD
Rasagiline—Pruritus—Triamcinolone—hematologic cancer	1.2e-05	5.66e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CB—hematologic cancer	1.2e-05	9.46e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MTOR—hematologic cancer	1.2e-05	9.46e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HSP90AA1—hematologic cancer	1.2e-05	9.45e-05	CbGpPWpGaD
Rasagiline—Cough—Methotrexate—hematologic cancer	1.2e-05	5.64e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD4—hematologic cancer	1.2e-05	9.44e-05	CbGpPWpGaD
Rasagiline—Mental disorder—Doxorubicin—hematologic cancer	1.2e-05	5.64e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FOXO1—hematologic cancer	1.2e-05	9.43e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDGFRB—hematologic cancer	1.2e-05	9.42e-05	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Epirubicin—hematologic cancer	1.19e-05	5.62e-05	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—hematologic cancer	1.19e-05	5.6e-05	CcSEcCtD
Rasagiline—Vomiting—Etoposide—hematologic cancer	1.19e-05	5.6e-05	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—hematologic cancer	1.19e-05	5.6e-05	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—hematologic cancer	1.19e-05	5.59e-05	CcSEcCtD
Rasagiline—Agitation—Epirubicin—hematologic cancer	1.18e-05	5.56e-05	CcSEcCtD
Rasagiline—Dyspepsia—Prednisone—hematologic cancer	1.18e-05	5.56e-05	CcSEcCtD
Rasagiline—Rash—Etoposide—hematologic cancer	1.18e-05	5.56e-05	CcSEcCtD
Rasagiline—Dermatitis—Etoposide—hematologic cancer	1.18e-05	5.55e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PDGFRA—hematologic cancer	1.18e-05	9.27e-05	CbGpPWpGaD
Rasagiline—Headache—Etoposide—hematologic cancer	1.17e-05	5.52e-05	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—hematologic cancer	1.17e-05	5.52e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—JAK1—hematologic cancer	1.17e-05	9.24e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PRKCG—hematologic cancer	1.17e-05	9.24e-05	CbGpPWpGaD
Rasagiline—Chest pain—Methotrexate—hematologic cancer	1.17e-05	5.51e-05	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—hematologic cancer	1.17e-05	5.51e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-B—hematologic cancer	1.17e-05	9.21e-05	CbGpPWpGaD
Rasagiline—Decreased appetite—Prednisone—hematologic cancer	1.17e-05	5.49e-05	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—hematologic cancer	1.17e-05	5.48e-05	CcSEcCtD
Rasagiline—Rash—Prednisolone—hematologic cancer	1.16e-05	5.48e-05	CcSEcCtD
Rasagiline—Dermatitis—Prednisolone—hematologic cancer	1.16e-05	5.48e-05	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.16e-05	5.47e-05	CcSEcCtD
Rasagiline—Malaise—Epirubicin—hematologic cancer	1.16e-05	5.46e-05	CcSEcCtD
Rasagiline—Headache—Prednisolone—hematologic cancer	1.16e-05	5.45e-05	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—hematologic cancer	1.16e-05	5.44e-05	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—hematologic cancer	1.16e-05	5.44e-05	CcSEcCtD
Rasagiline—Syncope—Epirubicin—hematologic cancer	1.15e-05	5.43e-05	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—hematologic cancer	1.15e-05	5.42e-05	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—hematologic cancer	1.15e-05	5.42e-05	CcSEcCtD
Rasagiline—Constipation—Prednisone—hematologic cancer	1.15e-05	5.4e-05	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—hematologic cancer	1.14e-05	5.38e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	1.14e-05	8.96e-05	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—hematologic cancer	1.13e-05	5.32e-05	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—hematologic cancer	1.13e-05	5.32e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1B—hematologic cancer	1.13e-05	8.88e-05	CbGpPWpGaD
Rasagiline—Dizziness—Triamcinolone—hematologic cancer	1.12e-05	5.29e-05	CcSEcCtD
Rasagiline—Cough—Epirubicin—hematologic cancer	1.12e-05	5.28e-05	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—hematologic cancer	1.11e-05	5.24e-05	CcSEcCtD
Rasagiline—Infection—Methotrexate—hematologic cancer	1.11e-05	5.24e-05	CcSEcCtD
Rasagiline—Nausea—Etoposide—hematologic cancer	1.11e-05	5.23e-05	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—hematologic cancer	1.11e-05	5.23e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisone—hematologic cancer	1.11e-05	5.21e-05	CcSEcCtD
Rasagiline—Asthenia—Betamethasone—hematologic cancer	1.11e-05	5.2e-05	CcSEcCtD
Rasagiline—Asthenia—Dexamethasone—hematologic cancer	1.11e-05	5.2e-05	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—hematologic cancer	1.1e-05	5.2e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—PHYH—hematologic cancer	1.1e-05	8.69e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GMPS—hematologic cancer	1.1e-05	8.69e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FTCD—hematologic cancer	1.1e-05	8.69e-05	CbGpPWpGaD
Rasagiline—Nervous system disorder—Methotrexate—hematologic cancer	1.1e-05	5.18e-05	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—hematologic cancer	1.1e-05	5.18e-05	CcSEcCtD
Rasagiline—Gastrointestinal pain—Prednisone—hematologic cancer	1.1e-05	5.16e-05	CcSEcCtD
Rasagiline—Nausea—Prednisolone—hematologic cancer	1.1e-05	5.16e-05	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—hematologic cancer	1.1e-05	5.15e-05	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—hematologic cancer	1.1e-05	5.15e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—IL2RA—hematologic cancer	1.1e-05	8.63e-05	CbGpPWpGaD
Rasagiline—Agitation—Doxorubicin—hematologic cancer	1.09e-05	5.15e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	1.09e-05	8.61e-05	CbGpPWpGaD
Rasagiline—Anxiety—Epirubicin—hematologic cancer	1.09e-05	5.14e-05	CcSEcCtD
Rasagiline—Pruritus—Dexamethasone—hematologic cancer	1.09e-05	5.13e-05	CcSEcCtD
Rasagiline—Pruritus—Betamethasone—hematologic cancer	1.09e-05	5.13e-05	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—hematologic cancer	1.09e-05	5.13e-05	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.09e-05	5.12e-05	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—hematologic cancer	1.08e-05	5.1e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-A—hematologic cancer	1.08e-05	8.53e-05	CbGpPWpGaD
Rasagiline—Discomfort—Epirubicin—hematologic cancer	1.08e-05	5.09e-05	CcSEcCtD
Rasagiline—Vomiting—Triamcinolone—hematologic cancer	1.08e-05	5.08e-05	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—hematologic cancer	1.07e-05	5.05e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—hematologic cancer	1.07e-05	8.45e-05	CbGpPWpGaD
Rasagiline—Rash—Triamcinolone—hematologic cancer	1.07e-05	5.04e-05	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—hematologic cancer	1.07e-05	5.04e-05	CcSEcCtD
Rasagiline—Dermatitis—Triamcinolone—hematologic cancer	1.07e-05	5.04e-05	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—hematologic cancer	1.07e-05	5.03e-05	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—hematologic cancer	1.07e-05	5.03e-05	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—hematologic cancer	1.07e-05	5.02e-05	CcSEcCtD
Rasagiline—Urticaria—Prednisone—hematologic cancer	1.07e-05	5.02e-05	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—hematologic cancer	1.07e-05	5.01e-05	CcSEcCtD
Rasagiline—Headache—Triamcinolone—hematologic cancer	1.06e-05	5.01e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTP1—hematologic cancer	1.06e-05	8.38e-05	CbGpPWpGaD
Rasagiline—Abdominal pain—Prednisone—hematologic cancer	1.06e-05	4.99e-05	CcSEcCtD
Rasagiline—Body temperature increased—Prednisone—hematologic cancer	1.06e-05	4.99e-05	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—hematologic cancer	1.06e-05	4.98e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PDGFB—hematologic cancer	1.06e-05	8.33e-05	CbGpPWpGaD
Rasagiline—Diarrhoea—Betamethasone—hematologic cancer	1.05e-05	4.96e-05	CcSEcCtD
Rasagiline—Diarrhoea—Dexamethasone—hematologic cancer	1.05e-05	4.96e-05	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—hematologic cancer	1.05e-05	4.93e-05	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—hematologic cancer	1.05e-05	4.92e-05	CcSEcCtD
Rasagiline—Infection—Epirubicin—hematologic cancer	1.04e-05	4.91e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	1.04e-05	8.2e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—hematologic cancer	1.04e-05	8.19e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BCL2L1—hematologic cancer	1.04e-05	8.19e-05	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—hematologic cancer	1.04e-05	4.89e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—hematologic cancer	1.04e-05	8.17e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TSC2—hematologic cancer	1.03e-05	8.14e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CRP—hematologic cancer	1.03e-05	8.14e-05	CbGpPWpGaD
Rasagiline—Shock—Epirubicin—hematologic cancer	1.03e-05	4.86e-05	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—hematologic cancer	1.03e-05	4.85e-05	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—hematologic cancer	1.03e-05	4.84e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	1.03e-05	8.11e-05	CbGpPWpGaD
Rasagiline—Hypertension—Doxorubicin—hematologic cancer	1.03e-05	4.84e-05	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.02e-05	4.81e-05	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—hematologic cancer	1.02e-05	4.8e-05	CcSEcCtD
Rasagiline—Dizziness—Dexamethasone—hematologic cancer	1.02e-05	4.8e-05	CcSEcCtD
Rasagiline—Dizziness—Betamethasone—hematologic cancer	1.02e-05	4.8e-05	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—hematologic cancer	1.01e-05	4.78e-05	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—hematologic cancer	1.01e-05	4.77e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK8—hematologic cancer	1.01e-05	7.99e-05	CbGpPWpGaD
Rasagiline—Arthralgia—Doxorubicin—hematologic cancer	1.01e-05	4.77e-05	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—hematologic cancer	1.01e-05	4.77e-05	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—hematologic cancer	1.01e-05	4.75e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—SMPD3—hematologic cancer	1.01e-05	7.95e-05	CbGpPWpGaD
Rasagiline—Nausea—Triamcinolone—hematologic cancer	1.01e-05	4.75e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—ABCB1—hematologic cancer	1.01e-05	7.94e-05	CbGpPWpGaD
Rasagiline—Paraesthesia—Methotrexate—hematologic cancer	1.01e-05	4.74e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	1.01e-05	7.93e-05	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.01e-05	4.74e-05	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—hematologic cancer	1e-05	4.71e-05	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—hematologic cancer	1e-05	4.71e-05	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—hematologic cancer	1e-05	4.71e-05	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—hematologic cancer	9.97e-06	4.69e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FGFR3—hematologic cancer	9.94e-06	7.83e-05	CbGpPWpGaD
Rasagiline—Dry mouth—Doxorubicin—hematologic cancer	9.91e-06	4.66e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—EP300—hematologic cancer	9.89e-06	7.79e-05	CbGpPWpGaD
Rasagiline—Hypersensitivity—Prednisone—hematologic cancer	9.89e-06	4.65e-05	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—hematologic cancer	9.87e-06	4.65e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—MAPK14—hematologic cancer	9.84e-06	7.75e-05	CbGpPWpGaD
Rasagiline—Hypotension—Epirubicin—hematologic cancer	9.81e-06	4.62e-05	CcSEcCtD
Rasagiline—Vomiting—Dexamethasone—hematologic cancer	9.8e-06	4.61e-05	CcSEcCtD
Rasagiline—Vomiting—Betamethasone—hematologic cancer	9.8e-06	4.61e-05	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—hematologic cancer	9.79e-06	4.61e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—NCOR1—hematologic cancer	9.78e-06	7.71e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTM1—hematologic cancer	9.78e-06	7.71e-05	CbGpPWpGaD
Rasagiline—Decreased appetite—Methotrexate—hematologic cancer	9.75e-06	4.59e-05	CcSEcCtD
Rasagiline—Rash—Betamethasone—hematologic cancer	9.72e-06	4.57e-05	CcSEcCtD
Rasagiline—Rash—Dexamethasone—hematologic cancer	9.72e-06	4.57e-05	CcSEcCtD
Rasagiline—Dermatitis—Betamethasone—hematologic cancer	9.71e-06	4.57e-05	CcSEcCtD
Rasagiline—Dermatitis—Dexamethasone—hematologic cancer	9.71e-06	4.57e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.68e-06	4.56e-05	CcSEcCtD
Rasagiline—Headache—Dexamethasone—hematologic cancer	9.65e-06	4.54e-05	CcSEcCtD
Rasagiline—Headache—Betamethasone—hematologic cancer	9.65e-06	4.54e-05	CcSEcCtD
Rasagiline—Infection—Doxorubicin—hematologic cancer	9.65e-06	4.54e-05	CcSEcCtD
Rasagiline—Asthenia—Prednisone—hematologic cancer	9.63e-06	4.53e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—hematologic cancer	9.62e-06	7.58e-05	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.56e-06	4.5e-05	CcSEcCtD
Rasagiline—Shock—Doxorubicin—hematologic cancer	9.56e-06	4.5e-05	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—hematologic cancer	9.53e-06	4.48e-05	CcSEcCtD
Rasagiline—Pruritus—Prednisone—hematologic cancer	9.5e-06	4.47e-05	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—hematologic cancer	9.49e-06	4.47e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—ICAM1—hematologic cancer	9.49e-06	7.48e-05	CbGpPWpGaD
Rasagiline—Skin disorder—Doxorubicin—hematologic cancer	9.43e-06	4.44e-05	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—hematologic cancer	9.43e-06	4.44e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—NFKBIA—hematologic cancer	9.42e-06	7.42e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BAD—hematologic cancer	9.42e-06	7.42e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	9.41e-06	7.41e-05	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Doxorubicin—hematologic cancer	9.39e-06	4.42e-05	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—hematologic cancer	9.36e-06	4.4e-05	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—hematologic cancer	9.33e-06	4.39e-05	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—hematologic cancer	9.26e-06	4.36e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRAS—hematologic cancer	9.25e-06	7.29e-05	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methotrexate—hematologic cancer	9.24e-06	4.35e-05	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—hematologic cancer	9.24e-06	4.35e-05	CcSEcCtD
Rasagiline—Diarrhoea—Prednisone—hematologic cancer	9.18e-06	4.32e-05	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—hematologic cancer	9.17e-06	4.32e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	9.17e-06	7.23e-05	CbGpPWpGaD
Rasagiline—Nausea—Dexamethasone—hematologic cancer	9.15e-06	4.31e-05	CcSEcCtD
Rasagiline—Nausea—Betamethasone—hematologic cancer	9.15e-06	4.31e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CD80—hematologic cancer	9.14e-06	7.2e-05	CbGpPWpGaD
Rasagiline—Decreased appetite—Epirubicin—hematologic cancer	9.13e-06	4.29e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—KIT—hematologic cancer	9.12e-06	7.19e-05	CbGpPWpGaD
Rasagiline—Hypotension—Doxorubicin—hematologic cancer	9.08e-06	4.27e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.06e-06	4.26e-05	CcSEcCtD
Rasagiline—Constipation—Epirubicin—hematologic cancer	8.98e-06	4.22e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PTPN11—hematologic cancer	8.96e-06	7.06e-05	CbGpPWpGaD
Rasagiline—Urticaria—Methotrexate—hematologic cancer	8.91e-06	4.19e-05	CcSEcCtD
Rasagiline—Dizziness—Prednisone—hematologic cancer	8.88e-06	4.18e-05	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—hematologic cancer	8.87e-06	4.17e-05	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—hematologic cancer	8.87e-06	4.17e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK3—hematologic cancer	8.86e-06	6.98e-05	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.85e-06	4.16e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—DCK—hematologic cancer	8.82e-06	6.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—B3GAT1—hematologic cancer	8.82e-06	6.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ASNS—hematologic cancer	8.82e-06	6.95e-05	CbGpPWpGaD
Rasagiline—Insomnia—Doxorubicin—hematologic cancer	8.78e-06	4.13e-05	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—hematologic cancer	8.72e-06	4.1e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FOS—hematologic cancer	8.7e-06	6.85e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CREB1—hematologic cancer	8.68e-06	6.84e-05	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—hematologic cancer	8.66e-06	4.08e-05	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—hematologic cancer	8.65e-06	4.07e-05	CcSEcCtD
Rasagiline—MAOB—Metabolism—MTHFR—hematologic cancer	8.64e-06	6.81e-05	CbGpPWpGaD
Rasagiline—Somnolence—Doxorubicin—hematologic cancer	8.63e-06	4.06e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	8.62e-06	6.79e-05	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Epirubicin—hematologic cancer	8.58e-06	4.04e-05	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—hematologic cancer	8.55e-06	4.02e-05	CcSEcCtD
Rasagiline—Vomiting—Prednisone—hematologic cancer	8.53e-06	4.02e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CASP8—hematologic cancer	8.5e-06	6.7e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6R—hematologic cancer	8.47e-06	6.67e-05	CbGpPWpGaD
Rasagiline—Rash—Prednisone—hematologic cancer	8.46e-06	3.98e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CREBBP—hematologic cancer	8.46e-06	6.66e-05	CbGpPWpGaD
Rasagiline—Dermatitis—Prednisone—hematologic cancer	8.45e-06	3.98e-05	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—hematologic cancer	8.44e-06	3.97e-05	CcSEcCtD
Rasagiline—Headache—Prednisone—hematologic cancer	8.41e-06	3.96e-05	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.39e-06	3.95e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—HDC—hematologic cancer	8.36e-06	6.59e-05	CbGpPWpGaD
Rasagiline—Urticaria—Epirubicin—hematologic cancer	8.34e-06	3.92e-05	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—hematologic cancer	8.31e-06	3.91e-05	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—hematologic cancer	8.3e-06	3.91e-05	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—hematologic cancer	8.3e-06	3.91e-05	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—hematologic cancer	8.26e-06	3.89e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—MAP2K1—hematologic cancer	8.07e-06	6.36e-05	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—hematologic cancer	8.05e-06	3.79e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—PIK3CD—hematologic cancer	8.02e-06	6.32e-05	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—hematologic cancer	8e-06	3.77e-05	CcSEcCtD
Rasagiline—Nausea—Prednisone—hematologic cancer	7.97e-06	3.75e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KRAS—hematologic cancer	7.96e-06	6.28e-05	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.94e-06	3.74e-05	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—hematologic cancer	7.94e-06	3.73e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	7.8e-06	6.14e-05	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—hematologic cancer	7.73e-06	3.64e-05	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—hematologic cancer	7.72e-06	3.63e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—FGF2—hematologic cancer	7.68e-06	6.05e-05	CbGpPWpGaD
Rasagiline—Abdominal pain—Doxorubicin—hematologic cancer	7.68e-06	3.61e-05	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—hematologic cancer	7.68e-06	3.61e-05	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—hematologic cancer	7.67e-06	3.61e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—CDA—hematologic cancer	7.65e-06	6.03e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3R1—hematologic cancer	7.57e-06	5.97e-05	CbGpPWpGaD
Rasagiline—Asthenia—Epirubicin—hematologic cancer	7.53e-06	3.54e-05	CcSEcCtD
Rasagiline—Pruritus—Epirubicin—hematologic cancer	7.43e-06	3.5e-05	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—hematologic cancer	7.42e-06	3.49e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—PC—hematologic cancer	7.36e-06	5.8e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JAK2—hematologic cancer	7.36e-06	5.8e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—hematologic cancer	7.32e-06	5.77e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—hematologic cancer	7.26e-06	5.72e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—hematologic cancer	7.22e-06	5.69e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MDM2—hematologic cancer	7.18e-06	5.66e-05	CbGpPWpGaD
Rasagiline—Diarrhoea—Epirubicin—hematologic cancer	7.18e-06	3.38e-05	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—hematologic cancer	7.16e-06	3.37e-05	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—hematologic cancer	7.13e-06	3.36e-05	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—SLC35B2—hematologic cancer	7.11e-06	5.6e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GBA—hematologic cancer	7.11e-06	5.6e-05	CbGpPWpGaD
Rasagiline—Rash—Methotrexate—hematologic cancer	7.07e-06	3.33e-05	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—hematologic cancer	7.07e-06	3.33e-05	CcSEcCtD
Rasagiline—Headache—Methotrexate—hematologic cancer	7.03e-06	3.31e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—MTOR—hematologic cancer	6.99e-06	5.51e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—hematologic cancer	6.99e-06	5.51e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—hematologic cancer	6.98e-06	5.5e-05	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—hematologic cancer	6.97e-06	3.28e-05	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—hematologic cancer	6.94e-06	3.27e-05	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—hematologic cancer	6.87e-06	3.23e-05	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—HRAS—hematologic cancer	6.77e-06	5.33e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CREBBP—hematologic cancer	6.73e-06	5.3e-05	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—hematologic cancer	6.67e-06	3.14e-05	CcSEcCtD
Rasagiline—Nausea—Methotrexate—hematologic cancer	6.66e-06	3.14e-05	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—hematologic cancer	6.65e-06	3.13e-05	CcSEcCtD
Rasagiline—Rash—Epirubicin—hematologic cancer	6.62e-06	3.11e-05	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—hematologic cancer	6.61e-06	3.11e-05	CcSEcCtD
Rasagiline—Headache—Epirubicin—hematologic cancer	6.58e-06	3.09e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CDKN1B—hematologic cancer	6.56e-06	5.17e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTAP—hematologic cancer	6.5e-06	5.12e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—hematologic cancer	6.48e-06	5.11e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—hematologic cancer	6.44e-06	5.08e-05	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—hematologic cancer	6.42e-06	3.02e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—IL2—hematologic cancer	6.42e-06	5.06e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—hematologic cancer	6.38e-06	5.03e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—hematologic cancer	6.3e-06	4.97e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—hematologic cancer	6.24e-06	4.92e-05	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—hematologic cancer	6.24e-06	2.93e-05	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—hematologic cancer	6.18e-06	2.91e-05	CcSEcCtD
Rasagiline—Rash—Doxorubicin—hematologic cancer	6.12e-06	2.88e-05	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—hematologic cancer	6.12e-06	2.88e-05	CcSEcCtD
Rasagiline—Headache—Doxorubicin—hematologic cancer	6.08e-06	2.86e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—CDKN1A—hematologic cancer	6.05e-06	4.77e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—hematologic cancer	6.04e-06	4.76e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3R1—hematologic cancer	6.03e-06	4.75e-05	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—hematologic cancer	5.98e-06	4.71e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK8—hematologic cancer	5.91e-06	4.66e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FHL2—hematologic cancer	5.8e-06	4.57e-05	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—hematologic cancer	5.77e-06	2.72e-05	CcSEcCtD
Rasagiline—BCL2—Immune System—EP300—hematologic cancer	5.76e-06	4.54e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AGRN—hematologic cancer	5.68e-06	4.48e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—hematologic cancer	5.6e-06	4.41e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—hematologic cancer	5.56e-06	4.38e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—hematologic cancer	5.4e-06	4.26e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—hematologic cancer	5.39e-06	4.25e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HMMR—hematologic cancer	5.39e-06	4.25e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH2—hematologic cancer	5.39e-06	4.25e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK3—hematologic cancer	5.16e-06	4.07e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	5.08e-06	4e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ARNTL—hematologic cancer	5.07e-06	3.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA9—hematologic cancer	4.93e-06	3.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACP5—hematologic cancer	4.93e-06	3.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOR2—hematologic cancer	4.86e-06	3.83e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—hematologic cancer	4.81e-06	3.79e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—hematologic cancer	4.64e-06	3.65e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH1—hematologic cancer	4.63e-06	3.65e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—hematologic cancer	4.58e-06	3.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCC3—hematologic cancer	4.58e-06	3.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TXN—hematologic cancer	4.58e-06	3.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTO1—hematologic cancer	4.58e-06	3.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SPHK1—hematologic cancer	4.48e-06	3.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGT1A1—hematologic cancer	4.31e-06	3.39e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—hematologic cancer	4.26e-06	3.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CRABP1—hematologic cancer	4.19e-06	3.3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC22A1—hematologic cancer	4.19e-06	3.3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALOX5—hematologic cancer	4.08e-06	3.22e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NUP98—hematologic cancer	3.96e-06	3.12e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—hematologic cancer	3.94e-06	3.11e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADCY7—hematologic cancer	3.84e-06	3.03e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOA3—hematologic cancer	3.84e-06	3.03e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NUP214—hematologic cancer	3.81e-06	3e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—hematologic cancer	3.77e-06	2.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.77e-06	2.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCG2—hematologic cancer	3.74e-06	2.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTR—hematologic cancer	3.74e-06	2.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO2—hematologic cancer	3.66e-06	2.89e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—hematologic cancer	3.55e-06	2.8e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.5e-06	2.76e-05	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—hematologic cancer	3.48e-06	2.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SDC1—hematologic cancer	3.47e-06	2.74e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—hematologic cancer	3.39e-06	2.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.32e-06	2.61e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.27e-06	2.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.13e-06	2.47e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CD44—hematologic cancer	2.95e-06	2.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NQO1—hematologic cancer	2.95e-06	2.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.89e-06	2.28e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYCS—hematologic cancer	2.79e-06	2.2e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.78e-06	2.19e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—hematologic cancer	2.77e-06	2.18e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.5e-06	1.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.46e-06	1.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.38e-06	1.88e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.33e-06	1.84e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.26e-06	1.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.26e-06	1.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—hematologic cancer	2e-06	1.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.76e-06	1.39e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.68e-06	1.32e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.56e-06	1.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.48e-06	1.16e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—hematologic cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.39e-06	1.1e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.29e-06	1.01e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—hematologic cancer	1.11e-06	8.77e-06	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—hematologic cancer	1.06e-06	8.36e-06	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—hematologic cancer	7.85e-07	6.18e-06	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—hematologic cancer	6.41e-07	5.05e-06	CbGpPWpGaD
